Piper Sandler analyst Sumeet Mody downgrades Virtus Investment (NASDAQ:VRTS) from Overweight to Neutral.
Autoimmune Disease Player Immunovant’s Investigational Drug For Immune System Disorder Shows Response Rates Of Over 50%
Immunovant Inc (NASDAQ: IMVT), on Thursday, released the results from the initial cohort of patients in an ongoing 24-week Phase 2 trial of batoclimab in